News

Myriad Genetics Achieves Significant Revenue Growth in 2024

Myriad Genetics Achieves Significant Revenue Growth in 2024

Myriad Genetics Reports Strong Financial Performance for 2024

Myriad Genetics, Inc. (NASDAQ: MYGN), a leading player in genetic testing and precision medicine, has announced impressive financial results for the fourth quarter and full-year ended December 31, 2024. The company has achieved a notable revenue of $838 million for the full year, marking an 11% increase compared to the previous year, showcasing continuous double-digit growth for the second consecutive year.

Quarterly Highlights

Fourth Quarter Financial Results

In the fourth quarter of 2024, Myriad Genetics generated revenue of $211 million, reflecting a 7% year-over-year increase. This surge in revenue was largely driven by strong demand for its Pharmacogenomics and Prenatal testing services, which grew by 14% and 12% respectively. Additionally, the company recorded a GAAP gross margin of 71.7%, a 300 basis point increase from the previous year.

Profitability and Cash Flow

Net Loss and Adjusted EBITDA

Despite the revenue growth, Myriad reported a GAAP net loss of $(43) million for the fourth quarter, totaling $(127) million for the entire year. However, adjusted EBITDA for these periods showed improvement, coming in at $11 million and $40 million respectively. As of the end of the fourth quarter, the company had approximately $158 million in cash and available borrowing capacity.

Strategic Initiatives in 2024

Innovative Collaborations and Leadership Changes

This past year has also been transformative for Myriad as they entered a strategic collaboration with PATHOMIQ to enhance their Oncology product offerings with artificial intelligence technology. This partnership includes exclusive rights to PATHOMIQ's AI platform tailored for prostate cancer, which will strengthen Myriad's existing Prolaris Prostate Cancer Prognostic Test.

On the leadership front, Myriad announced that Sam Raha, the current Chief Operating Officer, will take over as President and CEO, effective April 30, 2025, succeeding Paul J. Diaz. This leadership transition aims to further bolster the company’s strategic direction and operational excellence.

Outlook for 2025

Financial Guidance

Looking forward to 2025, Myriad Genetics reaffirmed its revenue guidance, projecting revenues between $840 million to $860 million, accompanied by an adjusted EPS range of $0.07 to $0.11. This outlook indicates an anticipated continued growth trajectory as the company plans to invest significantly in research and development to innovate its offerings further.

Frequently Asked Questions

What were Myriad Genetics' total revenues for 2024?

Myriad Genetics reported total revenues of $838 million for the full year of 2024, a growth of 11% year-over-year.

How did Myriad Genetics perform in the fourth quarter?

In the fourth quarter of 2024, Myriad Genetics achieved $211 million in revenue, marking a 7% increase from the previous year.

What innovations did Myriad Genetics introduce in 2024?

Myriad entered a strategic collaboration with PATHOMIQ to incorporate AI technology into its Oncology solutions, enhancing diagnostic capabilities.

Who will be the new CEO of Myriad Genetics?

Sam Raha, currently the Chief Operating Officer, will become the President and CEO of Myriad Genetics starting April 30, 2025.

What is the financial outlook for Myriad Genetics in 2025?

Myriad Genetics projects revenues between $840 million to $860 million for 2025, with an adjusted EPS forecast of $0.07 to $0.11.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Karoo Health Leaps Forward with New CCO Breton

Updated Category News Views 16

Change of Guard in Cardiac Health at Karoo Here's a move that might shake things up in the healthtech sector: Karoo Health just snagged Angela "Angie" Breton as their new Chief Commercial Officer. It's like putting a seasoned captain at the helm right before setting sail on uncharted waters. Breton's not just any captain—she's got a hefty 25 years of experience...

Continue Reading
Purina Institute Highlights Nutritional Science at WSAVA 2026

Updated Category News Views 19

A Global Stage for Pet Nutrition Science The folks over at the Purina Institute are back in the spotlight as they gear up to throw their weight behind the 51st World Small Animal Veterinary Association (WSAVA) Congress in Warsaw, Poland. Set for October 13-15, 2026, this isn’t just another event—they're bringing some serious clout with their 'Food for Thought'...

Continue Reading
ROKFORM’s Signal Card: A Wallet Tracker for All

Updated Category News Views 10

The Gadget You Didn't Know You Needed Ever feel that momentary panic when your wallet seems to have vanished into thin air? ROKFORM's fresh offering, the Signal Card, tackles that heart-stopping moment head-on. They've taken the mundane act of misplacing your wallet and transformed it with their sleek, credit-card-sized tracker. This baby pairs seamlessly with Apple Find...

Continue Reading
Community Banks Missing $106B Lending Opportunity?

Updated Category News Views 24

A Missed Opportunity for Community Banks It's a classic tale: community banks sleepwalking while big players snatch up low-hanging fruit right in their own backyards. According to the latest report by Cornerstone Advisors, commissioned by Teslar Software, these banks are essentially leaving $106 billion on the table when it comes to consumer lending. That's not just chump...

Continue Reading
Charter Next Generation Unveils Gen 2 MDO-PE Films

Updated Category News Views 14

Peering Into CNG's Latest Innovation Charter Next Generation (CNG) just threw down a hefty gauntlet with its launch of next-gen machine-direction-oriented polyethylene (MDO-PE) solutions. They're pushing the envelope on what recycle-ready packaging can do, folks. Let's not mince words—other players in the field better have their game faces on. This ain't just another...

Continue Reading
Cure Blindness Project's 770K Screenings for World Sight Day

Updated Category News Views 21

Visionary Steps Toward a Brighter Future No two words could describe the task that Cure Blindness Project is tackling this year: vision and action. Marking World Sight Day on October 8, they plan to usher in 770,000 eye screenings across Asia, Africa, and the Caribbean. These initiatives aren't just numbers—they're a colossal step toward lifting the veil of avoidable...

Continue Reading
TA Services Strengthens U.S.-Mexico Freight Operations

Updated Category News Views 22

TA Services Moves Boldly Across Borders If ever there was a time to play the logistics chessboard like a champ, it's now, and TA Services just slammed the board with a solid move. They've grabbed Carmen Pacheco Transportation and Interload Forwarding, two family-run operations with some real muscle in North American logistics. This isn't a small-time maneuver; they've...

Continue Reading
Epic Political Thriller Explores Humanity's Future

Updated Category News Views 12

Adams' Provocative Debut Asks Timeless Questions Sometimes life throws a philosophical curveball, and that's exactly what John C. Adams has done with his debut novel, The Third Phase. This isn't your average political yarn—it's an intricate tapestry intertwining political intrigue, deep spiritual inquiry, and hearty doses of classic philosophy. A Whirlwind Journey...

Continue Reading
Truss Financial Tackles Home Equity Closing Delays

Updated Category News Views 23

Truss Financial Group's Bold Move Against Closing Delays In real estate, time is money. Even the most casual market observer could tell you delays can slice through a deal like a hot knife through butter. That's the headache home equity borrowers face, blindsided by closing delays that sneak up on them without warning. An Industry Bottleneck Finally Addressed Enter Truss...

Continue Reading
Navigating Holiday Sweets: Healthy Balancing Acts

Updated Category News Views 21

In the middle of the sweet madness that is the holiday season, Crispy Green and Dr. Nicole Avena are playing guide to families drowning in sugar. This isn't just a once-a-year Halloween headache; we're starting that sugar spiral early and letting it ride until the New Year approaches. It's an all-hands-on-deck situation if families want to dodge that sugar overload. Why...

Continue Reading

Top 5 Most Recently Viewed Articles

Biogen's Breakthrough Journey: Felzartamab's Promise for Kidney Health

Updated Category News Views 173

Biogen’s Felzartamab Receives Breakthrough Therapy Designation Biogen (NASDAQ: BIIB) has achieved a significant milestone with its investigational antibody, felzartamab, which has been granted breakthrough therapy designation by regulatory authorities. This designation is a beacon of hope for patients suffering from late antibody-mediated rejection (AMR) in kidney...

Continue Reading
Soleno Therapeutics Investigated After Dramatic Share Drop

Updated Category News Views 190

Investor Concerns Surround Soleno Therapeutics Soleno Therapeutics, Inc. (NASDAQ: SLNO), a company dedicated to addressing the needs of individuals with rare disorders, recently drew considerable investor concern following a significant valuation drop of approximately 28%. This slump was catalyzed by the announcement regarding the performance of its drug VYKAT™ XR,...

Continue Reading
Top Tech Stocks Poised for a Dramatic Q1 Comeback

Updated Category News Views 157

Ready for a Technical Rollercoaster? Let's get straight to it. If you’re eyeing tech stocks, the hype around this sector doesn't hold a candle to the reality—it's become a chaotic market frenzy out there, and some real diamonds in the rough are just waiting to get snagged. Folks, we’re looking at oversold companies that might just bounce back like a rubber band. If...

Continue Reading
Traders Cautiously Eye Bitcoin's Support at $58,000 Level

Updated Category News Views 79

Traders Cautiously Eye Bitcoin's Support at $58,000 Level It seems that Bitcoin might be on the brink of another decline, sparking concern among traders as they focus on a possible dip beneath the $60,000 threshold. Analysts observing the BTC OrderBook heatmap have noted a significant concentration of buy orders near the $58,000 mark, establishing it as a strong support...

Continue Reading
Collins Aerospace Enhances UK Chinook Helicopters with New Tech

Updated Category News Views 98

Collins Aerospace Secures Contract for Chinook Upgrade Collins Aerospace, a prominent business within RTX, has been awarded a contract valued at $19 million by the Department of Defense. This significant contract aims to equip a fleet of H-47 Chinook helicopters operated by the UK Royal Air Force with a state-of-the-art avionics management suite known as the Common...

Continue Reading